clinical trial · NCT02492711
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
MacroGenics·phase3·completed·n = 624
HER-2 Positive Breast CancerMetastatic NeoplasmMargetuximabTrastuzumabPhysician's choice of chemotherapy.
brief summary
The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy. A non-randomized sub-study cohort of approximately 88 patients will be enrolled to evaluate the safety of a reduced margetuximab infusion rate in patients receiving margetuximab either as monotherapy or in combination with chemotherapy.
started
Aug 24, 2015
primary completion
Aug 11, 2021
completion
Jun 14, 2022
last updated
Mar 17, 2025
official title
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol